Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA’s Spring Regulatory Agenda Includes 17 Rx Drug-Related Rules

Executive Summary

FDA’s prescription drug regulations in the works include rules on generic drug labeling, compounding, bioequivalence reports and safety reporting for combination products.


Related Content

Dalvance: First QIDP Antibiotic Breaks New Regulatory Ground; Label Doesn’t
Electronic Labeling Study By GAO Yields “No Consensus,” Avoids Cost Issue
Combo Product Firms Want Simpler Adverse Event Reporting Structure
FDA “Xes” Letter Categories For Pregnancy Labels; Data Collection Drives Reg
National Licensing Standard For Wholesale Distributors Gains Momentum





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts